Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507493 | 1.00 | THRA (0.57) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL3507489 | 1.00 | THRA (0.57) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL29097361 | 0.93 | THRA (0.52) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL14416299 | 0.90 | THRA (0.47) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL7524928 | 0.90 | THRA (0.47) | THRATHRBLMNANPC1RAB9A | |
| Octadecanoic Acid Amide SCHEMBL29097633 | 0.88 | THRA (0.48) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL14123994 | 0.86 | NPC1 (0.52) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL4205511 | 0.86 | FFAR1 (0.49) | THRATHRBNPC1RAB9ABCHE | |
| SCHEMBL6026352 | 0.86 | THRA (0.55) | THRATHRBLMNANPC1RAB9A | |
| SCHEMBL12532976 | 0.84 | RAB9A (0.50) | THRATHRBLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113801200-A | Preparation method of carbetocin | 浙江湃肽生物有限公司 | 2021-12-17 | — | — | CN | claimed |
| CN-116947919-A | Fmoc-benzhydrylamine derivatives for synthesis of carbon-terminal amidated polypeptides and method for preparing same | 山西医科大学 | 2023-10-27 | — | — | CN | disclosed |
| EP-3778621-B1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO LTD (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219526-A2 | METHOD FOR PREPARING AMG 416 | AMGEN, INC. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-113801200-B | Preparation method of carbetocin | 浙江湃肽生物有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230099078-A1 | METHOD FOR PREPARING AMG 416 (ETELCALCETIDE) | AMGEN INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3708576-B1 | METHOD FOR PREPARING AMG 416 | AMGEN INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11377474-B2 | Method for preparing AMG 416 (etelcalcetide) | AMGEN INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-113801200-A | Preparation method of carbetocin | 浙江湃肽生物有限公司 | 2021-12-17 | — | — | CN | disclosed |
| US-20210139532-A1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO., LTD. (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0840804-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | DARWIN MOLECULAR CORPORATION (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027325-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-5565426-A | ANTI-AGGREGATION, INHIBTION OF BLOOD CLOTTING | ADIR ET COMPAGNIE (FR) | 1996-10-15 | — | — | US | disclosed |
| EP-0578535-B1 | New peptide derivates active in the process of cell adhesion, a method to prepare them end pharmaceutical compositions containing them | ADIR (FR) | 1996-08-21 | — | — | EP | disclosed |
| EP-0578535-A1 | New peptide derivates active in the process of cell adhesion, a method to prepare them end pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139532-A1 | PEPTIDE SYNTHESIS METHOD | NPPA, ANPEP, VIP | THRA 980/4885THRB 1405/4885LMNA 746/4885 |
| US-11377474-B2 | Method for preparing AMG 416 (etelcalcetide) | CYP24A1, PTH1R, MME | THRA 2266/4885THRB 2824/4885LMNA 1935/4885 |
| US-20230099078-A1 | METHOD FOR PREPARING AMG 416 (ETELCALCETIDE) | CYP24A1, PTH1R, MME | THRA 2266/4885THRB 2824/4885LMNA 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.